Allergan sells Rhofade for €65m

US-based Aclaris Therapeutics (Pennsylvania) has acquired global rights to Allergan’s Rhofade. The drug is a cutaneous therapy for the treatment of cutaneous facial erythema, which in 2011 was  included into Allergan’s portfolio following the acquisition of Vicept Therapeutics.

(Source: Aclaris)